Esperion Therapeutics

(NASDAQ) ESPR

Current Price$1.91

Market Cap$490.51M

Since IPO (2013)-87%

5 Year-93%

1 Year+111%

1 Month-30%

Esperion Therapeutics Financials at a Glance

Market Cap

$490.51M

Revenue (TTM)

$403.13M

Net Income (TTM)

$22.68M

EPS (TTM)

$-0.21

P/E Ratio

-9.12

Dividend

$0.00

Beta (Volatility)

1.02 (Average)

Dividend

$0.00

Beta (Volatility)

1.02 (Average)

Price

$1.91

Volume

183,529

Open

$1.93

Price

$1.91

Volume

183,529

Open

$1.93

Previous Close

$1.91

Daily Range

$1.89 - $2.02

52-Week Range

$0.69 - $4.17

Dividend

$0.00

Beta (Volatility)

1.02 (Average)

Price

$1.91

Volume

183,529

Open

$1.93

Previous Close

$1.91

Daily Range

$1.89 - $2.02

52-Week Range

$0.69 - $4.17

ESPR News

Should You Buy These 4 Biotech Stocks With Recent Drug Approvals?

David HaenApr 15, 2020

FDA Approves Esperion Therapeutics' New Cholesterol Drug

Mark PrvulovicFeb 21, 2020

4 Dates Biotech Investors Should Circle in February

Mark PrvulovicFeb 6, 2020

Page 1

ESPR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Esperion Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

294

CEO

Sheldon L. Koenig, MBA

Website

www.esperion.com

Headquarters

Ann Arbor, MI 48108, US

ESPR Financials

Key Financial Metrics (TTM)

Gross Margin

64%

Operating Margin

15%

Net Income Margin

-6%

Return on Equity

Return on Capital

37%

Return on Assets

-5%

Earnings Yield

-10.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$490.51M

Shares Outstanding

256.81M

Volume

183.53K

Avg. Volume

5.57M

Financials (TTM)

Gross Profit

$273.91M

Operating Income

$60.27M

EBITDA

$60.27M

Operating Cash Flow

$13.09M

Capital Expenditure

$189.00K

Free Cash Flow

$12.90M

Cash & ST Invst.

$167.85M

Total Debt

$548.00M

Esperion Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$168.45M

+143.7%

Gross Profit

$140.59M

+223.3%

Gross Margin

83.46%

N/A

Market Cap

$490.51M

N/A

Market Cap/Employee

$1.61M

N/A

Employees

304

N/A

Net Income

$61.83M

+390.0%

EBITDA

$85.23M

+1850.5%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$380.15M

-148.7%

Accounts Receivable

$140.19M

+74.9%

Inventory

$105.12M

+11.3%

Long Term Debt

$458.30M

+90.7%

Short Term Debt

$89.70M

+56.5%

Return on Assets

-4.87%

N/A

Return on Invested Capital

36.51%

N/A

Free Cash Flow

$45.43M

+230.0%

Operating Cash Flow

$45.24M

+229.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OFIXOrthofix Medical Inc.

OFIXOrthofix Medical Inc.$11.91-3.33%

RGNXREGENXBIO Inc.

RGNXREGENXBIO Inc.$8.69+0.81%

EBSEmergent BioSolutions Inc.

EBSEmergent BioSolutions Inc.$8.23+2.49%

AQSTAquestive Therapeutics, Inc.

AQSTAquestive Therapeutics, Inc.$4.09-0.24%

SNDLSNDL Inc.

SNDLSNDL Inc.$1.47-2.65%

SIGASIGA Technologies, Inc.

SIGASIGA Technologies, Inc.$4.59+0.66%

ABSIAbsci Corporation

ABSIAbsci Corporation$4.86+0.21%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$84.52-0.01%

NOKNokia

NOKNokia$11.30+0.05%

POETPoet Technologies

POETPoet Technologies$8.03+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$60.74-0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$12.14-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$18.36-0.02%

RIGTransocean

RIGTransocean$6.79+0.04%

Questions About ESPR

What is the current price of Esperion Therapeutics?

Esperion Therapeutics is trading at $1.91 per share.

What is the 52-week range for Esperion Therapeutics?

Over the past 52 weeks, Esperion Therapeutics has traded between $0.69 and $4.18.

How much debt does Esperion Therapeutics have?

As of the most recent reporting period, Esperion Therapeutics reported total debt of $548.00M.

How much cash does Esperion Therapeutics have on hand?

Esperion Therapeutics reported $167.85M in cash and cash equivalents in its most recent financial results.

What is Esperion Therapeutics’s dividend yield?

Esperion Therapeutics does not currently have a dividend yield.

Esperion Therapeutics

Esperion Therapeutics Financials at a Glance

ESPR News

Esperion (ESPR) Q2 Revenue Jumps 12%

Why Esperion Therapeutics Plummeted by 11% Today

Why Esperion Therapeutics Plummeted Nearly 22% Today

Why Esperion Therapeutics Stock Is Falling Today

3 New Drug Launches of 2020 -- and the Stocks That Could Win Big

Should You Buy These 4 Biotech Stocks With Recent Drug Approvals?

FDA Approves Esperion Therapeutics' New Cholesterol Drug

4 Dates Biotech Investors Should Circle in February

ESPR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Esperion Therapeutics

ESPR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Esperion Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ESPR

What is the current price of Esperion Therapeutics?

What is the 52-week range for Esperion Therapeutics?

How much debt does Esperion Therapeutics have?

How much cash does Esperion Therapeutics have on hand?

What is Esperion Therapeutics’s dividend yield?

Premium Investing Services